# 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia

> **NCT00381550** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 35 (actual)

## Conditions studied

- Accelerated Phase Chronic Myelogenous Leukemia
- Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Blastic Phase Chronic Myelogenous Leukemia
- Chronic Eosinophilic Leukemia
- Chronic Myelomonocytic Leukemia
- Essential Thrombocythemia
- Philadelphia Chromosome Negative Chronic Myelogenous Leukemia
- Polycythemia Vera
- Primary Myelofibrosis
- Relapsing Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** fludarabine phosphate
- **DRUG:** triapine
- **PROCEDURE:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00381550
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2015-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00381550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00381550, "3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00381550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*